NEW YORK, NY / ACCESSWIRE / November 20, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Golar LNG Limited (NASDAQ:GLNG)Class Period: April 30, 2020 - September 24, 2020Lead Plaintiff Deadline: November 23, 2020
According to the complaint, Golar LNG Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) certain employees, including the Chief Executive Officer of Hygo Energy Transition Ltd. f/k/a Golar Power Limited (“Hygo”), had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its initial public offering would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in GLNG: http://www.kleinstocklaw.com/pslra-1/golar-lng-limited-loss-submission-form?id=11119&from=1
Biogen Inc. (NASDAQ:BIIB)Class Period: October 22, 2019 - November 6, 2019Lead Plaintiff Deadline: January 12, 2021
The complaint alleges that throughout the class period Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11119&from=1
K12 Inc. (NYSE:LRN)Class Period: April 27, 2020 - September 18, 2020Lead Plaintiff Deadline: January 19, 2021
Throughout the class period, K12 Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.
Learn about your recoverable losses in LRN: http://www.kleinstocklaw.com/pslra-1/k12inc-loss-submission-form?id=11119&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: https://www.accesswire.com/617810/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-GLNG-BIIB-and-LRN